Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-07-10 am EDT			5-day change	1st Jan Change
455.55 ^DKK	+2.82%		+3.18%	-27.02%

Jul. 10	Mining, healthcare prop up European shares; US-EU trade talks in focus	RE
Jul. 09	Major deals involving U.S. drugmakers and biotechs over the past decade	RE

Novo Nordisk to Launch Late-stage Development of Amycretin Weight Management Treatment

Published on 06/12/2025 at 23:10

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novo Nordisk A/S

Mining, healthcare prop up European shares; US-EU trade talks in focus	Jul. 10	RE
Major deals involving U.S. drugmakers and biotechs over the past decade	Jul. 09	RE
European shares close at four-week high on banks boost; US trade talks in focus	Jul. 09	RE
Hims & Hers Times Pivot to Canada With Generic Weight-Loss Drug After Wegovy Fallout -- Update	Jul. 09	DJ
NOVO NORDISK : Deutsche Bank remains its Buy rating	Jul. 09	ZD
Europe rises despite new US tariff mayhem	Jul. 09	AN
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	Jul. 08	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	Jul. 08	MT
European shares rise on energy, healthcare boost; tariff uncertainty lingers	Jul. 08	RE
Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval	Jul. 08	RE
WeightWatchers names new medical chief, plans to offer menopause therapy and support	Jul. 08	RE
Novo Nordisk Seeks EU Approval for New, Higher Dose of Wegovy	Jul. 08	MT
Novo Nordisk Seeks EU Approval for Higher Dose of Weight-loss Drug Wegovy	Jul. 08	MT
Novo Nordisk Seeks Approval for Higher Dose of Wegovy	Jul. 08	FW
Novo Nordisk Seeks European Medicines Agency Approval for New, Higher Dose of Wegovy	Jul. 08	MT
Novo Nordisk submits new Wegovy dose to the European Medicines Agency for approval	Jul. 08	RE
Novo Nordisk submits application to EMA for approval of higher dose of Wegovy	Jul. 08	RE
WeightWatchers names new medical chief, plans to offer menopause therapy and support	Jul. 08	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	Jul. 07	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	Jul. 07	RE
The importance of being constantly changing…	Jul. 07
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	Jul. 07	RE
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	Jul. 07	RE
European shares fall as banks, mining stocks losses weigh	Jul. 04	RE
Jyske Bank Lowers Novo Nordisk Price Target to 700 Danish Kroner, Reiterates Buy - BN	Jul. 04	FW

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

77,406

Sector

Pharmaceuticals

Calendar

Aug. 06 - Q2 2025 Earnings Release

More about the company